Global law firm Eversheds has appointed former Sidley Austin London IP and Life Sciences Head, Brett Rowland as a Partner in its London office.
Prior to joining Sidley Austin in London, Brett was a Partner in the IP Group at Hogan Lovells.
Dual qualified in England and Australia, Brett has practised as a lawyer since 1988 and has specialised in Intellectual Property and Pharmaceutical Regulatory Law since 1991. His practice covers contentious and non-contentious work focusing increasingly on pharmaceuticals and biotech for some of the sector’s leading players. He has recently completed a 6 month secondment with the Swiss office of a major life sciences business giving him an in-depth exposure to industry issues.
As regulatory requirements increasingly affect the life sciences sector, Brett has handled a wide range of complex assignments and investigations in this business critical area.
In intellectual property, Brett has handled English High Court and Court of Appeal actions and Australian Supreme Court and Federal Court actions involving patent, branding and other IP disputes which have included applications for interim injunctions involving asset freezing and search and seizure orders.
Commenting on his appointment Brett said:
“I was drawn to Eversheds due to the firm’s commitment to growing its already broad international IP and life sciences practice which covers Europe the Middle East and Asia. I look forward to joining the team and working collaboratively in order to grow the existing practice.”
Simon Crossley, Head of IP and Life Sciences at Eversheds commented:
“We’re delighted to have secured Brett, he’s a key strategic hire in an area where we are seeing significant international growth and opportunity. He will be joining a specialist team and his experience, particularly in the life sciences regulatory area, will be a tremendous asset to our clients.”
Bill Gilliam, Head of the Health & Life Sciences Sector Group at Eversheds commented:
“Brett’s experience will be a great asset to the life sciences team as we continue to expand the scope of work we carry out for our pharma and life sciences clients. We look forward to welcoming him to the firm.”
